326 related articles for article (PubMed ID: 29536296)
21. Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis.
Kang SH; Min SH; Kim JW; Lee E; Park SW; Lee S; Oh HJ; Park YS; Lee YJ; Kim JW; Ahn SH; Suh YS; Lee KW; Lee HS; Kim HH
Ann Surg Oncol; 2022 Aug; 29(8):5084-5091. PubMed ID: 35322307
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Ishigami H; Kitayama J; Kaisaki S; Hidemura A; Kato M; Otani K; Kamei T; Soma D; Miyato H; Yamashita H; Nagawa H
Ann Oncol; 2010 Jan; 21(1):67-70. PubMed ID: 19605503
[TBL] [Abstract][Full Text] [Related]
23. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Wu Z; Ma S; Jing S; Deng Q; Zheng Z; Wu K; Li J; Chen S; Tang R; Li X
Hepatogastroenterology; 2014 Jun; 61(132):972-7. PubMed ID: 26158151
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
[TBL] [Abstract][Full Text] [Related]
25. [A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
Iwai N; Wakabayashi N; Matsumoto N; Morita Y; Tanaka N; Yoriki H; Fujii K; Takada R; Takaya H; Masuzawa A; Takami S; Kataoka K
Gan To Kagaku Ryoho; 2015 Mar; 42(3):351-4. PubMed ID: 25812506
[TBL] [Abstract][Full Text] [Related]
26. Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection.
Imano M; Imamoto H; Itoh T; Satou T; Peng YF; Yasuda A; Kato H; Shiraishi O; Shinkai M; Yasuda T; Takeyama Y; Okuno K; Shiozaki H
J Surg Oncol; 2012 Jan; 105(1):43-7. PubMed ID: 21837682
[TBL] [Abstract][Full Text] [Related]
27. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
Satoi S; Fujii T; Yanagimoto H; Motoi F; Kurata M; Takahara N; Yamada S; Yamamoto T; Mizuma M; Honda G; Isayama H; Unno M; Kodera Y; Ishigami H; Kon M
Ann Surg; 2017 Feb; 265(2):397-401. PubMed ID: 28059968
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding.
Choi MK; Ahn BJ; Yim DS; Park YS; Kim S; Sohn TS; Noh JH; Heo JS; Lee J; Park SH; Park JO; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jan; 67(1):5-11. PubMed ID: 20213078
[TBL] [Abstract][Full Text] [Related]
29. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
30. Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
Anticancer Res; 2018 Oct; 38(10):5969-5974. PubMed ID: 30275227
[TBL] [Abstract][Full Text] [Related]
31. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.
Ishigami H; Fujiwara Y; Fukushima R; Nashimoto A; Yabusaki H; Imano M; Imamoto H; Kodera Y; Uenosono Y; Amagai K; Kadowaki S; Miwa H; Yamaguchi H; Yamaguchi T; Miyaji T; Kitayama J
J Clin Oncol; 2018 Jul; 36(19):1922-1929. PubMed ID: 29746229
[TBL] [Abstract][Full Text] [Related]
32. Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma.
Kodera Y; Ito Y; Ito S; Ohashi N; Mochizuki Y; Yamamura Y; Koike M; Fujiwara M; Nakanishi H; Nakao A
Hepatogastroenterology; 2007; 54(75):960-3. PubMed ID: 17591103
[TBL] [Abstract][Full Text] [Related]
33. [A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally].
Kato K; Koide A; Oobu M; Hasegawa K; Maruyama S; Takashima I; Nagahama T; Maruyama M; Ebuchi M
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1852-4. PubMed ID: 15553737
[TBL] [Abstract][Full Text] [Related]
34. Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial).
Misawa K; Mochizuki Y; Sakai M; Teramoto H; Morimoto D; Nakayama H; Tanaka N; Matsui T; Ito Y; Ito S; Tanaka K; Uemura K; Morita S; Kodera Y;
Br J Surg; 2019 Nov; 106(12):1602-1610. PubMed ID: 31573086
[TBL] [Abstract][Full Text] [Related]
35. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
[TBL] [Abstract][Full Text] [Related]
36. [Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].
Bamba T; Kanda T; Ohashi M; Hanyu T; Sakamoto K; Ishikawa T; Yajima K; Makino S; Tanabe T; Kosugi S; Hatakeyama K
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1695-7. PubMed ID: 16315912
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
Ishigami H; Kitayama J; Kaisaki S; Yamaguchi H; Yamashita H; Emoto S; Nagawa H
Oncology; 2010; 79(3-4):269-72. PubMed ID: 21372602
[TBL] [Abstract][Full Text] [Related]
38. [Progress in conversion therapy for stage IV gastric cancer].
Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):107-111. PubMed ID: 33508914
[TBL] [Abstract][Full Text] [Related]
39. [Intraperitoneal Chemotherapy for Peritoneal Metastasis of Gastric Cancer].
Yamaguchi H; Ishigami H; Kitayama J
Gan To Kagaku Ryoho; 2016 Dec; 43(13):2481-2485. PubMed ID: 28028253
[TBL] [Abstract][Full Text] [Related]
40. Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol.
Vatandoust S; Bright T; Roy AC; Watson D; Gan S; Bull J; Abbas MN; Karapetis CS
BMJ Open; 2019 May; 9(5):e026732. PubMed ID: 31061042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
